Burgevin Alice, Caron Bénédicte, Sasson Alexa, Luc Amandine, Netter Patrick, Baumann Cédric, Ananthakrishnan Ashwin N, Peyrin-Biroulet Laurent
Department of Gastroenterology, University Hospital of Nancy, F-54000 Nancy, France.
NGERE (Nutrition-Génétique et Exposition aux Risques Environnementaux), U1256 INSERM, University of Lorraine, F-54000 Nancy, France.
J Clin Med. 2022 Nov 25;11(23):6967. doi: 10.3390/jcm11236967.
Introduction: Data about the safety of vedolizumab and ustekinumab are lacking in older patients with inflammatory bowel disease. The objective was to compare the safety of vedolizumab and ustekinumab therapies in older patients (>60 years) with inflammatory bowel disease. Methods: This retrospective study included patients with Crohn’s disease or ulcerative colitis initiating vedolizumab, ustekinumab or anti-TNF therapy at >60 years of age. We examined the occurrence of adverse events within one year after therapy. Results: This study included 182 patients: 53 were treated with vedolizumab (22 patients with Crohn’s disease and 31 with ulcerative colitis), 31 with ustekinumab (30 Crohn’s disease and one ulcerative colitis) and 98 with anti-TNF (63 Crohn’s disease and 35 ulcerative colitis). At one year, there was no difference in terms of safety in patients with Crohn’s disease between vedolizumab and ustekinumab considering the number of adverse events per year of follow-up (p = 0.258). For ulcerative colitis and Crohn’s disease, the occurrence of adverse events per year of follow-up was similar between vedolizumab and anti-TNF (p = 0.274 and p = 0.876, respectively). Conclusions: Safety was similar between vedolizumab and ustekinumab in older patients with inflammatory bowel disease.
老年炎症性肠病患者缺乏关于维多珠单抗和乌司奴单抗安全性的数据。目的是比较维多珠单抗和乌司奴单抗疗法在老年（>60岁）炎症性肠病患者中的安全性。方法：这项回顾性研究纳入了年龄>60岁开始使用维多珠单抗、乌司奴单抗或抗TNF治疗的克罗恩病或溃疡性结肠炎患者。我们检查了治疗后一年内不良事件的发生情况。结果：本研究纳入了182例患者：53例接受维多珠单抗治疗（22例克罗恩病患者和31例溃疡性结肠炎患者），31例接受乌司奴单抗治疗（30例克罗恩病患者和1例溃疡性结肠炎患者），98例接受抗TNF治疗（63例克罗恩病患者和35例溃疡性结肠炎患者）。随访一年时，考虑到每年随访的不良事件数量，维多珠单抗和乌司奴单抗治疗的克罗恩病患者在安全性方面没有差异（p = 0.258）。对于溃疡性结肠炎和克罗恩病，维多珠单抗和抗TNF治疗每年随访的不良事件发生率相似（分别为p = 0.274和p = 0.876）。结论：在老年炎症性肠病患者中，维多珠单抗和乌司奴单抗的安全性相似。
